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Expression of insulin-like growth factor and its binding protein genes
during nephrogenesis. To study the role of insulin-like growth factors
(IGF5) and their binding proteins (IGFBP5) in human nephrogenesis, we
examined the temporal and spatial pattern of expression of these genes
using in situ hybridization. The uninduced metanephric blastema (MB)
expressed abundant IGF-II mRNA. With induction by the ureterie duct
(UD), the aggregated MB additionally expressed IGFBP-2 and IGFBP-4
mRNAs. The mature UD expressed IGFBP-3 mRNA while the ampulla in
contact with the MB lacked IGFBP-3 mRNA and expressed IGFBP-2
exclusively. Upon formation of the S-shape nephron, IGFBP-2 mRNA
was expressed in the committed glomerular and epithelial cells which also
expressed IGF-II and IGFBP-4, and the mesenchyme of the vascular cleft
expressed IGFBP-5 mRNA. In the maturing glomerulus, the glomerular
epithelial cells expressed IGF-II mRNA together with IGFBP-2 and
IGFBP-4 mRNAs, while IGFBP-5 mRNA was localized to the mesangium
and supporting mesenchyme. As the proximal tubule was formed the
epithelium expressed less of IGFBP-2 mRNA and more of IGFBP-4
mRNA. The renal mesenchyme in the cortex and medulla expressed
abundant IGF-II mRNA, and lower levels of IGFBP-4 and -5 mRNAs.
The epithelium of the collecting ducts and pelvicalyceal system expressed
abundant IGFBP-3. In contrast, IGF-I, IGFBP-1, and tGFBP-6 mRNAs
were expressed at low levels. The specific temporal and spatial pattern of
expression of IGFBP genes on the background of abundant IGF-II gene
expression suggests that the IGFBP peptides, as modulators of IGF action,
are expressed locally at specific points of nephrogenesis to interact with
IGF-II to regulate mesenchymal induction, renal epithelial cell commit-
ment, differentiation and growth.
Nephrogenesis remains a poorly understood process. The pre-
cise morphological events which occur from induction of the
metanephric blastema to the development of the mature glomer-
ulus have been reviewed previously [1—3]. In vivo experiments
pioneered by Grobstein et al suggest that reciprocal induction of
the ureterie duet and metanephrie blastema is mediated through
direct cell contact and intercellular communication [4, 5]. Various
polypeptide growth factors, including epidermal growth factor
(EGF) and transforming growth factors (TGFs) [6], fibroblast
growth factors (FGFs) [7], and the insulin-like growth factors I
and II (IGF-I and IGF-II) [8, 9], have been implicated as
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modulators of tissue differentiation and specifically nephrogen-
esis.
Both IGF-I and IGF-II are ubiquitous peptides which exert
numerous biological effects, including mitogenie and differentia-
tive effects and insulin-like metabolic effects on a variety of cell
types [10—12]. The demonstration of IGF-II mRNA [13] IGF
immunoreactivity [14], and IGF receptors [15] in human fetal
kidneys, and the stimulation of metanephric growth and segmen-
tal tubular differentiation in metanephric organ cultures by IGFs
[6, 16] suggested a role for IGFs in nephrogenesis.
While the biological actions of IGFs are mediated through
interaction with cell surface receptors, the IGFs also interact with
a family of IGF binding proteins (IGFBPs). Six IGFBPs have
been identified, their cDNAs cloned, and named IGFBP-1 to -6
[17]. In the circulation, IGFBPs are important in prolonging
half-lives of IGFs and in facilitating the transfer of IGFs across
the capillaries [18, 19]. The role of IGFBPs in nephrogenesis is
undefined. In the human fetal circulation, IGFs are bound
predominantly to IGFBP-3, with a smaller proportion bound to
the other smaller IGFBPs [20]. Since mRNAs encoding IGFBPs,
like those encoding IGFs, are expressed widely in multiple human
fetal tissues [21, 22] including the kidney, it is likely that IGFs and
IGFBPs are synthesized locally within the developing kidney and
regulate the various cellular events of nephrogenesis.
In the intercellular space, IGFBPs either inhibit or potentiate
IGF action by modulating their interaction with cell surface
receptors [19]. Recently, we have demonstrated that the bifunc-
tional nature of IGFBP action may depend on the relative
molarity between IGFs and IGFBPs, and the capacity of IGFBPs
to associate with cell surfaces [23, 24]. The purpose of this study
is to describe the normal developmental expression of the IGF
and IGFBP mRNAs in early human nephrogenesis utilizing in situ
hybridization. Since IGFs and IGFBPs are paracrine factors, the
sites of IGF and IGFBP mRNA expression likely indicate the sites
of biological action. The temporal and spatial pattern of expres-
sion of IGF and IGFBP mRNAs in specific cell types in the
developing human fetal kidney most likely indicates the stages of
nephrogenesis in which these peptides play a regulatory role.
Methods
Kidney tissues
Kidneys were obtained from therapeutically aborted human
fetuses between the ages of eight to 14 weeks gestation after
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informed consent and in accordance with approval from the
Human Ethics Committees of the University of Western Ontario,
London, Ontario and McGill University, Montreal, Quebec.
Kidneys were dissected within thirty minutes of the operative
procedure, cut longitudinally, and fixed in 4% paraformaldehyde
and 0.2% glutaraldehyde in 70 m phosphate buffer, pH 7.0 at
4°C for 16 to 18 hours, embedded in paraffin, and 0.5 sm tissue
sections were prepared by standard methods and mounted onto
SuperFrostTM microscope slides (Fisher Scientific, Unionville,
Ontario, Canada).
Immunohistochemistty
Immunohistochemistry was performed as previously described
[25]. Briefly, tissue sections were deparaffinized in xylene, rehy-
drated and washed in phosphate buffered saline (PBS). Endoge-
nous peroxidase activity was quenched by incubating tissue sec-
tions in 3% hydrogen peroxide (in PBS) for 30 minutes. They were
next incubated in 10% normal goat serum and then with specific
primary antisera overnight at 4°C. The primary antibodies that
were used included a rabbit polyclonal antiserum against cyto-
keratin (1:2500) and a mouse monoclonal antibody against
smooth muscle actin (1:500) (Sigma, St. Louis, Missouri, USA).
Sections were then washed in PBS and positive immunoreactivity
(IR) was identified by the avidin-biotin-peroxidase technique
using the Vectastain kit (Vector Laboratories, Burlingame, Cali-
fornia, USA) with diaminobenzidine as the chromagen. Tissue
sections were then counterstained with Carazzi's hematoxylin,
dehydrated and mounted with PermountTM (Fisher Scientific, Fair
Lawn, New Jersey, USA).
In situ hybridization histochemistry
In situ hybridization was performed by a previously described
method, with some modifications [26]. Tissue sections were
deparaffinized, rehydrated in descending ethanol series (100%,
90%, 70%), and incubated in the following solutions: 0.2%
Triton-X 100 in PBS, proteinase-K (1 mgfml), and acetic anhy-
dride (0.25%) in triethanolamine buffer (Sigma). The sections
were dehydrated in ascending ethanol series and prehybridized
with ix hybridization buffer (0.3 M NaCl, 20 mM TrisHCl pH 8.0,
1 m EDTA, ix Denhardt's solution, 500 jig/mI yeast tRNA, 100
jig/mI denatured salmon sperm DNA, 10% dextran sulfate, 0.1%
SDS, 100 mM dithiothrietol, and 50% formamide) at 42°C. Tissue
sections were then hybridized with 35S-labeled antisense RNA
probes generated from linearized cDNAs, radiolabeled to specific
activities of io9 cpm/gg and used at concentrations of 1 X 106
cpm/ml in lx hybridization buffer (as above) overnight at 55°C,
and washed as follows: 1 x SSC at room temperature for 15
minutes twice, 0.1 x SSC at room temperature for 30 minutes
twice, and 0.1 x SSC at 55°C for 30 minutes twice. Tissue sections
were then dehydrated in ascending ethanol series and exposed to
X-ray film (XAR, Kodak Laboratories, Rochester, New York,
USA) for 18 to 20 hours at —70°C. The slides were coated with
photoemulsion (NTB-3 nuclear track emulsion, Kodak Laborato-
ries) and exposed at 4°C for three to 18 days. The duration for
exposure to photoemulsion was judged by the autoradiographic
intensity of the sections exposed to X-ray film overnight. The
photoemulsion was developed with a D-19 developer (Kodak
Laboratories), fixed, stained with Harris's hematoxylin and eosin,
and mounted with PermountTM. The slides were viewed under
both dark and bright fields using an Aristoplantm photomicro-
scope (Wild Leitz Ltd., Germany). Two to three sets of duplicate
slides were tested. The cDNAs used in this study included hIGF-I
and hJGF-II cDNAs (gifts from M. Jansen, University of Utrecht,
The Netherlands [27, 28]) and hIGFBPs -ito -6 (gifts from S.
Shimasaki, Scripps Memorial Clinic, LaJolla, California [17]). All
of the cDNAs encoding total or partial coding regions were
subcloned into pGEM 42 (IGF-J and -II) or pBluescript SK+ or
KS + vectors (IGFBPs 1 through 6) and linearized using appro-
priate restriction enzymes of the multi-cloning site.
The specificity of in situ hybridization was demonstrated by the
abolition of specific hybridization signal when adjacent tissue
sections were subjected to an identical in situ hybridization
procedure with (i) radiolabeled sense RNA probes (Fig. iB), and
(ii) RNAse pretreatment of tissue sections prior to hybridization
with radiolabeled cRNA probes (Fig. iD).
Combined in situ hybridization and immunohistochemistty
To identify the cell types that demonstrated positive hybridiza-
tion, in situ hybridization was combined on the same tissue
sections with cytokeratin (Ci) immunohistochemistry to identify
epithelial cell types. For this combined procedure, tissue sections
underwent in situ hybridization with 35S-labeled cRNA probes as
described above up to and including the stage of washing. Tissue
sections were then incubated overnight with a specific antiserum
against cytokeratin at 4°C, and the immunoreactivity (IR) was
identified using the avidin-biotin-peroxidase technique up to the
stage of reaction with diaminobenzidine. The sections were then
dehydrated in ascending ethanol series, air dried, coated with
NTB-3 photoemulsion, and exposed for three to 18 days at 4°C.
The photoemulsion was then developed, fixed, counterstained
with Carazzi's hematoxylin, and mounted with PermountTM. The
slides were viewed under both dark and bright fields as above.
Results
Cellular identification
The developing kidney was divided into two stages for analysis:
(1) the early developing nephron, consisting of the uninduced
metanephric blastema (MB), the induced blastema aggregate, the
S-shape nephron and the ureteric duct (UD) and ampulla, (Table
1) and, (2) the maturing nephron, consisting of the recognizable
nephron with differentiated endothelial, epithelial and mesangial
cells, along with functional proximal and distal tubules and
collecting ducts (Table 2).
Cytokeratin (CT) and smooth muscle actin (SMA) immunore-
activity were used to help identify the various uninduced and
induced epithelial and mesenchymal structures (Fig. 2). In the
early developing nephron, there was intense CT immunoreactivity
(CT-IR) in the inducing ureteric duct epithelium, up to but not
including the ampulla. There was a less intense immunostaining of
the proximal tubular epithelium (Figs. 3A and 4A). With induc-
tion of differentiation, the aggregated metanephric blastema and
S-shape nephron structures demonstrated circumferential CT-JR.
In the maturing nephron structures, CT-JR was localized in the
visceral (podocyte) and parietal glomerular epithelium, the ure-
teric duct, distal tubule and, less intensely, in the proximal tubule
epithelium and mesenchyme (Figs. 5A and 6A).
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Fig. 1. Dark-fl eld photomicrographs of in situ hybridization in the early developing kidney using various 35S-labeled RNA probes to demonstrate specificity
to: (A) IGF-JI cRI'JA, (B) IGF-II sense Rb/A, (C) JGFBP-2 cR1 VA, and (B) IGFBP-2 cRNA pretreated with RNAse prior to hybridization. Scale bar = 100
jim.
Smooth muscle actin IR was localized in the undifferentiated development of the S-shape nephron, SMA-IR was observed in
metanephric blastema cells and the undifferentiated mesenchyme the mesenchyme cells within the vascular cleft and in the mesang-
(data not shown). With the induction of differentiation and ial cells of the mature glomerulus (Fig. 2A through D).
/9,
1
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Fig. 2. Smooth muscle actin immunoreactivity (SMA-IR) in the developing kidney. (A) Immunoreactivity in the early developing kidney showing SMA-IR
in the vascular cleft of the developing S-shape nephron (small arrowheads), and in the smooth muscle of a small renal vessel (ye). Abbreviations are:
v, visceral glomerular epithelium; p, parietal glomerular epithelium; m, mesangium. Scale bar = 100 m. (B) SMA-IR in the mesangium of the maturing
glomerulus. Abbreviation is: c, capillary. Scale bar = 50 m. (C) Higher magnification Nomarski view of (B). Abbreviation is: bs, Bowman's space. Scalebar = 25 sm. (D) Nomarski view of intrarenal vessel immunostained with smooth muscle actin antiserum showing SMA-IR in the vascular smooth
muscle (sm). Abbreviation is: e, vascular endothelium. Scale bar = 25 jm.
IGF and IGFBP mRNAs
Except for minor differences, the spatial pattern of expression
of IGF and IGFBP mRNAs was similar in all three gestational
ages (8, 12 and 14 weeks). This was because all stages of renal
development were observed within the developing kidney of 14
weeks gestation. In general, IGF mRNAs (IGF-II in particular)
were expressed predominantly in the mesenchymal cell types
(undifferentiated metanephric blastema and differentiated renal
mesenchyme), whereas IGFBPmRNAs were expressed in both
the epithelial and mesenchymal cell types, with each IGFBP
demonstrating a specific spatial and temporal pattern.
IGFs. IGF-II mRNA was expressed abundantly in the cells of
the undifferentiated metanephric blastema and supporting mes-
enchyme (Figs. 3B and 4B), and to a lesser extent in the cells of
the developing S-shape nephron, including those destined to
become visceral and parietal glomerular epithelium (Fig. 4B). In
the maturing nephron, IGF-II mRNA was expressed abundantly
in the mesenchymal cells, and less abundantly in the mesangium
and visceral epithelium of the maturing glomerulus (Figs. 5B and
6B).
IGFBPs. IGFBP-2 mRNA was expressed most dramatically in
the early developing stages of the nephron. At these stages, the
mRNA was identified in the cells of the induced aggregated
blastema, the differentiated visceral and parietal glomerular epi-
thelial cells of the S-shape nephron, the differentiating proximal
tubular epithelial cells, and in the actively proliferating cells of the
ampulla of the ureteric duct (Figs. 3C and 4C). In the more
mature glomerulus, the IGFBP-2 mRNA was identified in the
differentiated visceral and parietal glomerular epithelial cells, and
the proximal tubular epithelial cells (Figs. 5C and 6C). IGFBP-2
mRNA was the only IGFBP mRNA expressed in the ampulla.
IGFBP-3 mRNA was expressed specifically in the ureteric duct
of the early developing stages of the nephron with the exception
of the ampulla. In addition, it was observed in the small nests of
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Fig. 3. Dark-field photomicrograph of in situ hybridization in the early developing kidney with 35S-labeled cRNA probes to (B) IGF-II, (C) IGFBP-2, (D)
IGFBP-3, (E) 1GFBP-4, (F) IGFBP-5. (A) Bright-field photomicrograph of representative area of early developing kidney immunostained with a
cytokeratin antiserum. Abbreviations are: c, capsule; mb, metanephric blastema cells; u, ureteric duct, S, S-shape nephron; v, visceral epithelial cells;
and m, mesenchyme. Scale bar = 100 m.
cells within the undifferentiated mesenchyme (Figs. 3D and 4D). collecting system, exclusively expressed IGFBP-3 mRNA (Figs.
In the mature kidney, epithelial cells of those structures derived 4D, 5D and 6D).
from the ureteric duct, including the stratified epithelium of the In the early developing stages of the nephron, IGFBP-4 mRNA
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Fig. 4. Bright-field photomicrograph of in Situ hybridization in the early developing kidney with 35S-labeled cRNA probes to (B) IGF-II, (C) IGFBP-2, (D)
IGFBP-3, (E) IGFBP-4, (F) IGFBP-5. (A) Adjacent tissue section stained with a cytokeratin antiserum. Sections are immunostained with a cytokeratin
antiserum. Abbreviations are: c, capsule; mb, metanephric blastema cells; a, ampulla; u, ureteric duct; S, S-shape nephron; v, visceral epithelial cells;
p, parietal epithelial cells; and m, mesenchyme. Scale bar = 50 .tm.
was expressed discretely in the differentiating glomerular visceral the glomerulus, IGFBP-4 mRNA was expressed in the visceral
and parietal epithelial cells of the aggregated blastema and the glomerular epithelial cells and the proximal tubular epithelium
S-shape nephron (Figs. 3E and 4E). With further maturation of (Figs. 5E and 6E).
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Table 1. IGF/IGFBP mRNA expression in the early developing nephron
IGF I IOF II BP1 BP2 BP3 BP4 BP5 BP6
Uninduced metanephric blastema + + + + + — — — + — +
Induced/aggregated blastema + + + + + — + + + — + + — +
S-shape/comma:
Committed tubular + — — +++ — — — +
Committed epithelial ++++ — ++++ — ++++ — +
Mesenchymal derived + — — — — — + + + —
Uretericduct + — — — +++ — — +
Ampulla ÷ — — +++ — — — +
Cellular sites and relative abundance of IGF and IGFBP mRNAs in the early developing nephron. Scoring was done by two observers independently,
and in the case of discrepancy, a consensus score was decided following discussion. Scoring: — is absent; + is present in low abundance above
background; + + is moderate abundance; + + + is high abundance; + + + + is very high abundance.
Although IGFBP-5 mRNA was expressed predominantly in the
more developed kidney, it was also observed in the epithelial cell
layer of the renal capsule and outer zone of the metanephric
blastema. IGFBP-5 mRNA was identified specifically in the rays
of undifferentiated mesenchymal cells extending from the cortex
to medulla of the kidney, and in the mesenchymal cells extending
into the glomerular vascular cleft of the S-shape nephron (Figs. 3F
and 4F). IGFBP-5 mRNA was expressed abundantly in the
mesangium of the glomeruli of the more mature kidney (Figs. SF
and 6F). In both the early developing and maturing nephron, only
low levels of IGF-I, IGFBP-1, and IGFBP-6 mRNA expression
were observed.
A summary of cellular sites and relative abundance of expres-
sion of each IGF and IGFBP mRNA in the early developing
nephron and the maturing nephron in the human fetal kidney is
shown in Tables 1 and 2, respectively.
Discussion
We have demonstrated a distinct temporal and spatial expres-
sion of IGF and IGFBP mRNAs in the developing human fetal
kidney (Fig. 7). The on and off expression of IGFBP genes at
specific stages of renal development on the background of IGF-II
mRNA expression in the metanephric blastema and the mesen-
chymal elements suggests that these IGFBP peptides are synthe-
sized locally at specific sites to modulate IGF action by a paracrine
or autocrine mechanism.
IGF-I and IGF-II mRNAs have been demonstrated in almost
every tissue of the developing human fetus as early as 16 weeks
gestation, with significantly higher IGF-II mRNA levels in the
early gestation [14}. After liver and adrenal gland, the developing
kidney is one of the human fetal tissues expressing the highest
levels of IGF-II mRNAs. In situ hybridization showed IGF-II
mRNA to be higher in the undifferentiated metanephric blastema
and to be slightly less in the renal interstitium as previously
reported [26, 29]. The metanephric blastema is of mesodermal
origin and is undergoing a high degree of cellular proliferation
and differentiation at this gestation. The high level of IGF-II
mRNA expressed in these cells suggests IUF-Il to be an important
autocrine/paracrine growth factor for their development. IGFs
are potent mitogens as well as differentiation-promoting factors
[19] and are therefore well suited to regulate the development of
the metanephric blastema. IGF-I mRNA was expressed only at
low levels in the developing human fetal kidney, suggesting that
IOF-I may be less important at this stage in the developing human
fetus [22]. The role of IGFs in the development of the metaneph-
nc blastema was demonstrated by studies which showed that the
developing rat metanephri in organ culture produced both IGF-I
and IGF-II, and growth and development of the metanephri in
this system were prevented by the addition of anti-IGF-I and
anti-IOF-Il antibodies [16].
Less is known about the role of IGFBPs in the process of fetal
kidney development. Of the six IGFBPs cloned to date, the
expression of some IGFBP mRNAs has been demonstrated in
both the fetal and adult kidneys [21]. IGFBP-1 mRNA expression
was demonstrated in the human fetal kidneys between 15 to 23
weeks gestation by both Northern blotting and in situ hybridiza-
tion. The IGFBP-1 mRNA localized preferentially to the collect-
ing duct epithelium, developing glomerular cells, and the neph-
rogenic mesenchyme [30]. The IGFBP-2 mRNA was detected in
kidneys of the fetal rat [31] and the fetal sheep [32]. In the latter,
IGFBP-2 mRNA levels are high in early gestation, and decrease
with maturation, paralleling IGF-II mRNA expression. The kid-
ney is one of the few organs that continues to express IGFBP-2
mRNA into adulthood.
The present study is the first to identify the temporal and spatial
pattern of expression of IGFBP genes in relation to IGF-II gene
expression in normal human nephrogenesis. This expression
appeared to occur at particular points of induction and differen-
tiation of the nephron. Within the tissue environment, IGFBPs
either inhibit or potentiate the biological actions of IGFs [33—391.
Even though their role in human nephrogenesis is unknown, they
most likely modulate the actions of IGFs at discrete cellular sites
of the developing kidney. In addition, the recent demonstration of
the IGF-independent actions of IGFBPs suggests that some
IGFBPs may have biological actions of their own during nephro-
genesis.
The IGFBP mRNAs are expressed at times and within cells
where they likely are modulating the action of IGF-II. The
expression of IGFBP-2 mRNA in the aggregated cells of the
metanephric blastema and the ampulla of the ureteric duct
suggests that IGFBP-2 regulates glomerular epithelial cell differ-
entiation. We have previously shown that IGFBP-2 has a dual
function, based on the relative molar concentrations between the
peptide and IGF-II present in the extracellular milieu [23]. It is
therefore conceivable that IGFBP-2 produced by the ampulla of
the ureteric duct interacts with the IGF-II produced by the
metanephric blastema to initiate the aggregation and differentia-
tion of the cells into the S-shape nephron. IGFBP-3, on the other
hand, was expressed predominantly in the mature and differenti-
ated cells of the collecting system and ureteric duct, losing its
expression as the tip of the ureteric duct forms the ampulla. The
ampulla is comprised of undifferentiated or dedifferentiated cells,
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Fig. 5. Dark-field photomicrograph of in situ hybridization in the maturing kidney with 35S-labeled cRNA probes to (B) IGF-II, (C) IGFBP-2, (D) IGFBP-3,
(E) IGFBP-4, (F) IGFBP-5. (A) Bright-field photomicrograph of representative area of maturing kidney immunostained with cytokeratin antiserum.
Abbreviations are: g, glomerulus; pt, proximal tubule; d, distal tubule; m, mesenchyme. Scale bar = 100 jim.
as evident by its loss of CT-IR. IGFBP-3 has been shown to inhibit with reduced growth rate, which may be independent of lOPs [41].
the mitogenic actions of lOPs [40] and recently it was shown that The pattern of expression of IGFBP-3, therefore, corresponded
overexpression of this gene in transfected CHO cells is associated with the differentiation and dedifferentiation of the ureteric duct,
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Table 2. IGF/IGFBP mRNA expression in the maturing nephron
IGF I IGF II BP1 BP2 BP3 BP4 BP5 BP6
Maturing glomerulus:
Endothelial + — — — — — —
Epithelial + +++ — ++++ — ++++ — +
Mesangial -I-- — — — — — + + + + —
Proximal tubule + — — + + — + + + — +
Distal tubule + — — — + + — — +
Collecting system + — — — + + + + — — +
Supporting mesenchyme + ++ + —1+ + ++ ++÷+ +
Cellular sites and relative abundance of IGF and IGFBP mRNAs in the maturing nephron. Scoring was done by two observers independently, and
in the case of discrepancy, a consensus score was decided following discussion. Scoring: — is absent; + ispresent in low abundance above background;
+ + is moderate abundance; + + + is high abundance; + + + + is very high abundance.
2. Induced
Metanephric
Blastema
3. S-shape
Nephron
the more mature cells suggests that this peptide maintains these
cells in the mature phenotype. IGFBP-5 mRNA was expressed
almost exclusively in the mesenchymal cell types and was more
abundant in the cells that subsequently developed into the
glomerular endothelial and mesangial cells. IGFBP-5 is associated
with the extracellular matrix proteins, which may serve as a store
for this IGFBP [421. The pattern of expression of this gene in the
mesenchymal cells invading the glomerular cleft and in the mature
glomerulus suggests its involvement in angiogenesis of the gb-
merulus. This is further supported by the pattern of SMA-IR in
the developing kidney. The undifferentiated mesenchymal cells,
the cells invading the vascular cleft, and those destined to become
glomerular mesangial cells, demonstrated abundant SMA-IR.
This supports the view that vascularization of the glomerulus and
development of the mesangium involves mesenchymal cell inva-
sion and differentiation, which may be modulated by IGFBP-5
expression in these cells. Thus, different biological actions of the
same growth factor, IGF-II, in the same cells may be achieved by
expression of different IGFBPs by these or adjacent cells.
It is noteworthy that the temporal and spatial expression of the
IGFBPs parallels that of certain well-described transcription
factors. These include the homeodomain proteins encoded by the
homeobox gene Pax-2 which is expressed in the early metanephric
blastema and S-shape nephron and has been implicated in the
induction of metanephric mesenchyme to renal epithelium [43].
Most of the IGFBP genes are in chromosomal locations in close
1. Uninduced
Metanephric
Blastema
4. Maturing
Glomerulus
Fig. 7. Schematic illustration of the temporal and spatial expression of IGF and IGFBP mRNA during nephrogenesis. For the purposes of discussion,
nephrogenesis is divided into four recognizable stages: (1) uninduced metanephric blastema, (2) induced metanephric blastema, (3) S-shape nephron,
and (4) maturing glomerulus. The IGF and IOFBP mRNA are represented spatially at that particular stage.
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proximity to the homeobox genes, suggesting the importance of
IGFBPs during development and perhaps that these two gene
families share similar ancestry. The spatial and temporal expres-
sion of the transcriptional factor genes is similar to IGFBP-2
mRNA expression, and to a certain extent to IGFBP-4 mRNA
expression. These correlations suggest the possibility that the
expression of IGFBP mRNAs (specifically IGFBP-2 and
IGFBP-4) may be under the control of these transcriptional
factors. For example, the WT-1 gene localized on chromosome
lipl3, encodes a DNA-binding protein which binds to an IGF-II
gene promoter site, resulting in repression of IGF-II transcription
[44]. Further study is required to delineate the expression of IGF
and IGFBP genes in the well recognized syndromes of renal
dysplasia, to address the hypothesis that these peptides are
important in normal and abnormal nephrogenesis.
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